1178 related articles for article (PubMed ID: 11352963)
21. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
23. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Ritter J; Creutzig U; Schellong G
Leukemia; 1992; 6 Suppl 2():59-62. PubMed ID: 1578943
[TBL] [Abstract][Full Text] [Related]
24. [Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Starý J; Gajdos P; Blazek B; Ptoszková H; Hrstková H; Kopecná L; Tousovská K; Hak J; Procházková D; Cerná Z; Jabali Y; Timr P; Vávra V; Sedlácek P; Smísek P; Hrusák O; Michalová K
Cas Lek Cesk; 2004; 143(4):257-63. PubMed ID: 15218726
[TBL] [Abstract][Full Text] [Related]
25. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
Dluzniewska A; Balwierz W; Armata J; Balcerska A; Chybicka A; Kowalczyk J; Matysiak M; Ochocka M; Radwanska U; Rokicka-Milewska R; Sonta-Jakimczyk D; Wachowiak J; Wysocki M
Leukemia; 2005 Dec; 19(12):2117-24. PubMed ID: 16107894
[TBL] [Abstract][Full Text] [Related]
26. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
[TBL] [Abstract][Full Text] [Related]
28. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
30. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
[TBL] [Abstract][Full Text] [Related]
31. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
32. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
33. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
34. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
35. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
36. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
37. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
38. Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Creutzig U; Dworzak M; Zimmermann M; Bourquin JP; Gruhn B; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; von Stackelberg A; Stray J; Reinhardt D
Klin Padiatr; 2015 May; 227(3):116-22. PubMed ID: 25985446
[TBL] [Abstract][Full Text] [Related]
39. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
